Inovio has announced today that it has partnered with Medimmune (part of Astra-Zeneca) to exploit the capabilities of Interlukin 12 (also called IL-12 or INO=3112). IL-12 increases the amount of t cell response and shortens the time needed for the t cells to appear to fight an antigen.
The various grants and progress payments Inovio now has amount to close to a Billion dollars. In addition, the Company has close to $200M for research, corporate purposes and some studies ongoing or planned.
Inovio now has grants or partnerships with NIH, DARPA, Hoffman La Roche, European cancer organization (EPRTC) and now Medimmune. It has programs against cancers and infectious disease.
The stock of the Company was up near 30% today and finished on huge volume.
Monday, August 10, 2015
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment